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Anti-idiotypic antibodies  have been  used  to demonstrate  unique  idiotypic deter- 
minants on the cell surface of affected clones of peripheral blood lymphocytes from 
patients  with  macroglobulinemia  (1),  multiple  myeloma (2-6),  benign  monoclonal 
gammopathy  (7),  and  chronic  lymphocytic  leukemia  associated  with  monoclonal 
gammopathy (8-11).  Although  multiple myeloma is classically considered  a  malig- 
nancy  of  bone  marrow  plasma  cells,  the  above  studies  have  suggested  that  B- 
lymphocyte clonal  ancestors of the  malignant  plasma cells may also  be expanded. 
Reports of the existence of both T  and  B  lymphocytes bearing  identical  idiotypic 
(Id) l determinants in two patients with IgGx myelomas (5, 6)  suggest that the target 
cell  for oncogenic  transformation  could  be a  precursor  cell  for both  B- and  T-cell 
clones. 
It is now evident from ontogenetic studies in mammals (man, mouse, and rabbit) 
that the appearance of B lymphocytes bearing surface IgM in fetal liver is preceded 
by the development of a population of lymphoid cells, which contain small amounts 
of cytoplasmic  IgM  components  but  lack  surface  immunoglobulins  detectable  by 
immunofluorescent  techniques  (12-14). These pre-B cells are presumed to be direct 
precursors of B  lymphoyctes (15-17).  After lympho-hemopoiesis ceases in  fetal liver, 
large, rapidly dividing pre-B cells are found exclusively in the bone marrow (12-14), 
which  is  now recognized  as the adult  source of newly  generated  B  lymphocytes in 
mammals  (18,  19),  analogous  to  the  avian bursa of Fabricius  (20).  It  has recently 
been found that in ~-20% of individuals with childhood acute lymphocytic leukemia, 
* Supported by grants CA 16673 and CA 13148, awarded by the National Cancer Institute; DHEW, 
RR32, F32 CA 05776, AI 11502, and AI 12127 from the National Institutes of Health; and IN-66Q from 
American Cancer Society. 
1Abbreviations used in  this paper: BSA, bovine serum albumin; Cohn Fx  II, pooled normal human 
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the malignant cells have the pre-B cell phenotype (21). Possible involvement of pre-B 
cells in other malignancies of B-cell lineage has not been investigated. 
In this study, we have used antibodies against idiotypic determinants of myeloma 
proteins to analyze the developmental history of multiple myelomas by immunoflu- 
orescent techniques.  The homologous idiotypic determinants were found exclusively 
in  plasma cells containing IgA in  two  patients with  IgA myeloma, whereas  on  the 
surface  of circulating  B  lymphocytes  the  same  determinants  were  associated  with 
different immunoglobulin classes. An expanded population of IgM-containing pre-B 
cells  expressing  the  homologous  idiotype  was  found  in  each  patient,  whereas  T 
lymphocytes were  not  found  to  express  the  idiotypic determinants.  These  findings 
point to oncogenic transformation  very early in the life history of an  affected B-cell 
clone in multiple myeloma. 
Materials  and  Methods 
Isolation and  Characterization of Monoclonal Immunoglobulins.  Sera  were  collected  from  two 
patients  with  IgA  myeloma,  IgA,  (001)  and  IgAx  (003),  before  therapy.  Crude  globulins, 
isolated from serum by precipitation with sodium sulfate, were dialyzed against 0.01  M  Tris- 
HCI buffer, pH 8.0 and applied to a column of DEAE cellulose (DE 52, Whatman Inc., Clifton, 
N. J.) equilibrated with the same buffer. Fractions containing myeloma IgA were eluted with 
a linear gradient to 0.5 M  NaCI-0.01  M  Tris-HCl buffer pH 8.0, and chromatographed on a 
column of Sephadex G-200 (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, 
N. J.) equilibrated with borate-saline buffer, pH 8.3 (ionic strength =  0.1). The exclusion peak 
containing  polymeric IgA  was  collected and  concentrated.  Residual  IgG  was  removed  by 
passage over an affinity column bearing rabbit antibodies to human  y-chains. The purity of 
IgA  paraproteins was  tested  by  immunoelectrophoresis and  double  diffusion in  agar  with 
antisera to normal human serum proteins, IgG, IgA, and IgM. Heavy and light chains were 
prepared from purified myeloma immunoglobulins by reduction and alkylation followed by 
separation on Sephadex G-200 in 5 M  guanidine-HCI, pH 7.2. 
Amino-terminal sequencing to 20 residues was used to ascertain VH and VL subgroups (22). 
IgA protein 001  had a Vrn heavy chain and V,t light chain; IgA 003 was VHn and Vxlv. IgA 
myeloma proteins BLK and STC were selected as matches for 001  and 003 with respect to VH 
and VL subgroups as well as CH and CL sequence. 
Immunization.  1 mg  of purified  myeloma protein  in  complete  Freund's adjuvant  (Difco 
Laboratories,  Detroit,  Mich.)  was  injected  subcutaneously  into  rabbits  or  goats.  Booster 
injections, with  1 mg of myeloma protein in incomplete Freund's adjuvant, were given two to 
four times at  10-d intervals from day 14 after primary immunization. 
Preparation of Anti-idiotypic Antibodies.  Solid immunoadsorbent  columns  were prepared by 
covalent attachment of normal serum proteins or myeloma proteins to Sepharose 4B activated 
with cyanogen bromide (23).  Antisera were absorbed sequentially to remove unwanted speci- 
ficities; each absorption was repeated until the quantity of absorbed protein eluted from the 
column by 0.05  M  glycine-HCl buffer, pH 2.8,  was less than 0.5 rag. The absorbed antisera 
were then passed over a column containing the homologous myeloma protein and the bound 
anti-Id antibodies eluted. A representative absorption sequence is shown in Table I in which 
the relative yield of anti-Id is indicated. 
Direct Hemagglutination Assays.  Human erythrocytes (type 0, Rh+)  were coated with mye- 
loma proteins or normal human  immunoglobulins (Cohn Fx II) or anti-Id antibodies by the 
chromic chloride method (24).  Serial dilutions of purified goat or rabbit anti-Id or goat anti- 
human  F(ab')2  antibodies  in  phosphate-buffer  saline  (PBS)  containing  5%  bovine  serum 
albumin (BSA) were prepared in plastic microwells (Cooke Laboratory Products, Alexandria, 
Va.)  to  which  immunoglobulin-coated erythrocytes were  added.  As a  reciprocal test, serial 
dilutions of myeloma proteins or Cohn Fx II were mixed with anti-Id coated erythrocytes. 
Solid-phase Inhibition Radioimmunoassay.  Purified myeloma proteins IgA~ (001) and IgAx (003), 
were labeled with carrier-free 125I (New England Nuclear, Boston, Mass.) by the chloramine T 
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4 h  at room temperature with 0.5 p.g/ml of purified anti-Id. These quantities were based on 
preliminary estimates  of amounts  of antibody  which  would  bind  30%  of the  125I-labeled 
homologous myelomas. In some experiments, polystyrene tubes were coated with saturating 
amounts of anti-Id antibodies. After washing out excess antibody with PBS and coating free 
sites on tubes with 0.1% BSA in PBS, several concentrations of different inhibitor proteins were 
added to the antibody-coated tubes in triplicate and incubated for 1 h at 37°C.  100 p.l of ~2~I- 
labeled homologous myeloma protein (4  ×  10  s cpm/ml) was then added to each tube for an 
additional 20 h at 37°C. Unbound radioactivity was washed out with PBS and the tubes were 
counted in a gamma counter. 
Conjugation.  F(ab')2 fragments of rabbit anti-Id antibodies were prepared by pepsin digestion 
(26),  separated from residual intact molecules by chromatography on Sephadex G-150, and 
then absorbed with Staphylococcal Protein A  (Pharmacia Fine Chemicala, Div. of Pharmacia 
Inc.) coupled to Sepharose 4B. Purified F(ab')2 fragments of rabbit anti-Id, or intact goat anti- 
Id,  were  conjugated  with  fluorescein  isothiocyanate  (FITC)  or  rhodamine  isothiocyanate 
(RITC) as previously described (27). 
Imrnunofluorescence Analysis of Cells.  Peripheral blood lymphocytes, isolated by Ficoll (Phar- 
macia  Fine Chemicals,  Div.  of Pharmacia  Inc.)-Hypaque  (Winthrop  Laboratories,  N.  Y.) 
gradient centrifugation and bone marrow cells, depleted of mature erythrocytes by lysis with a 
hypotonic solution of ammonium  chloride, were washed with  PBS  supplemented with  10% 
fetal calf serum  (FCS)  (Gibco Diagnostics, Gibco Invenex Div., Chagrin Falls, Ohio), resus- 
pended in RPMI-1640 medium (Grand Island Biological Co., Grand Island, N. Y.) containing 
20%  FCS and  incubated in plastic dishes for 45  min  at  37°C  to remove adherent cells and 
cytophilic immunoglobulin. To characterize the cells bearing idiotypic determinants, previously 
described methods  for two-color immunofluorescence were used  for double staining of cell- 
surface immunoglobulins, simultaneous staining of cell-surface and cytoplasmic immunoglob- 
ulins and sequential staining of two cytoplasmic immunoglobulin determinants with FITC- or 
RITC-labeled antibodies (13).  The  antibodies used  for counterstaining with  fluorochrome- 
labeled anti-Id antibodies included purified goat antibodies with the following specificities for 
human  immunoglobulin determinants:  anti-/~,  anti-g, anti-y, anti-a, anti-F(ab')2, anti-~ and 
anti-~ prepared as described elsewhere (13). 
T- and B-Cell Separation.  T  cells were isolated from peripheral blood by rosette formation 
with  neuraminidase-treated sheep  erythrocytes  (SRBC)  and  density gradient separation  as 
described (28). The contamination of the T-cell-enriched fraction with surface immunoglobulin- 
positive cells was < 1%. Fluoresceinated rabbit antiserum for the detection of human T cells was 
kindly supplied by Dr. Charles M. Balch et al. (29). 
Results 
Specificity  of Purified  Anti-idiotypic  Antibodies.  The  specificity  of  purified  anti-Id 
antibodies was studied by two sensitive assays, direct hemagglutination and inhibition 
radioimmunoassay. Less than 0.1 ng/ml of homologous myeloma protein agglutinated 
erythrocytes coated with purified anti-Id, more than  107 times greater concentrations 
of pooled  normal  immunoglobulins  (Cohn  Fx  II  protein),  or  of myeloma  proteins 
matched  for  heavy-chain  class,  light-chain  type,  and  VH  and  VL  subgroups,  were 
required to achieve hemagglutination  (Table II). Comparable results were obtained 
when the reverse assay, in which anti-Id antibodies were used to agglutinate antigen- 
coated erythrocytes. 
Radioimmunoassays indicated that both anti-Id (001)  and anti-Id (003)  recognize 
determinants  of both  light  and  heavy chains  of the  homologous  myeloma proteins 
(Fig.  1). However, the inhibitory capacity (50% inhibition) of the isolated chains was 
at  least  100-fold less than  that  of the intact  myeloma proteins. Neither Cohn  Fx II 
protein  nor  other  IgA  myeloma  proteins  inhibited  binding of anti-Id  (001)  at  the 
highest concentrations tested, whereas for anti-Id (003), 5  ×  106 ng/ml ofCohn  Fx II 
protein  gave  25%  of the  inhibition  that  was  given  by 4  ng/ml  of IgAa (003).  Even H.  KUBAGAWA  ET  AL. 
TABLE  I 
Purification of Goat Antibodies to Idiotypic Determinants of IgA Myeloma 
Protein (001) 
[mmunoadsorbent  columns  Percentage of total 
bound antibodies* 
IgG, (x 2)*  38.4 
IgM~  3.3 
IgG~  0.8 
Normal IgG (× 3)  6.4 
Normal F(ab')2  1.0 
IgA~ (FH) (× 2)  26.0 
IgA~(BG) (× 2)  1.0 
IgAa (JP)  0.9 
Cohn Fx II protein  0.1 
IgA~ (001)  22.1§ 
* Quantity of protein eluted from each column divided by the total proteins 
eluted from all columns times 100. 
* Numbers in parentheses indicate multiple column absorptions. 
§ From an initial aliquot of 45 ml of goat anti-lgA, (001) antiserum, 33.7 mg 
of anti-Id (001) antibodies were obtained. In different sera, anti-ld antibodies 
represented  10-20% of the total antibodies reactive with  immunoglobulin 
determinants. 
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TABLE II 
Specificity Test of Purified Anti-idiotype Antibodies 
Erythrocyte-coating  Hemagglutinating  Minimum amount for 
antibodies  protein  hemagg[utination 
ng/ml 
Anti-Id (001)  IgA, (001)*  <0.03 
Anti-Id (001)  IgA~ (BLK)*  1,000,000 
Anti-ld (001)  Cohn Fx I]  10,000,000 
Anti-Id (003)  IgAx (003)*  <0.1 
Anti-ld (003)  IgAx (STC)*  >1,000,000 
Anti-Id (003)  Cohn Fx II  >10,000,000 
* VH and VL subgroups of these two myeloma proteins were the same based 
on the analysis of N-terminal 20 amino acids; VHI and Vet, 
VHII and Vxiv. 
when tubes were coated with saturating amounts of anti-Id antibodies, IgA myeloma 
proteins  matched  for  light-chain  type  and  VH  and  VL  subgroups  did  not  inhibit 
binding at the highest concentration tested (3  ×  104 ng/ml). 
Expression of Idiotypic Determinants on  Lymphocytes from  Normal Donors.  Given  their 
apparent  specificity for  the  immunizing  myelomas  in  the  hemagg|utination  assays 
and radioimmunoassay, fluorochrome-labeled anti-Id antibodies stained a surprisingly 
high proportion of B lymphocytes from normal donors (Table III). Goat anti-Id (001) 
stained 0.8  -+  0.3%  of sIg  ÷  cells, whereas  F(ab')z fragments  of rabbit  anti-Id  (003) 
stained 0.5  -+ 0.3%. The staining of normal lymphocytes by F(ab')2 fragments of anti- 
Id  antibodies  was  completely  inhibited  in  the  presence  of a  16-fold  excess  of the 
homologous myeloma protein, but was not inhibited by myeloma proteins of the same 
heavy-chain  isotype, light-chain class and  VH  and VL subgroup.  Idiotypic determi- 
nants were found  in association with all classes of cell surface immunoglobulins but 796  IDIOTYPE  EXPRESSION  IN  PRECURSORS OF  MYELOMA CELLS 
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Fro.  1.  Effect of various inhibitor proteins on the binding of 12sI-IgA, (001) by anti-Id (001). Each 
point is the average of triplicate assays. Polystyrene  tubes were coated with 0.5 p.g/ml  of anti-Id 
(001), which gave 30% of maximum binding of 125I-IgA, (001). IgA, (001) (O), a-chain (001) (A), 
r-chain (001) (11), Cohn Fx II proteins (×), and unrelated IgA myeloma protein (O) were used as 
inhibitors. 
TABLE  III 
Expression of Myeloma-related Idiotypes on Peripheral B Lymphocytes from Six Normal Subjects * 
A.  Frequency of Id  ÷ cells among B lymphocytes bearing different isotypes 
Id  Id  Id  Id 
Idiotype  ~+  ~+  + 
Ig  +  y 
Id 
~+ 
001  0.8 ±  0.3  1.2  4- 0.4  1.3  ±  0.4  1,3  4- 0.9  0.6  4- 0.3 
003  0.5  4- 0.3  0.6 4- 0.3  0.6 ±  0.5  1,2  ±  0,4  0.4  ±  0.1 
B.  Distribution ofisotype among Id  ÷ B lymphocytes 
#+Id +  6+Id  +  y+Id  +  a+ld  ÷ 
Idiotype  Id  +  Id  ÷  |d  +  Id  + 
001  73  ±  18  74  4-  19  55  ±  38  8 ±  4 
003  73  ±  31  67  ±  21  71  4-  27  l0  ±  I 
C.  Distribution oflight chain type among Id  ÷ B lymphocytes 
K+Id  +  h+Id + 
Idiotype  Id  +  Id  ÷ 
001  75  4-  21  25  ±  21 
003  1 4-  3  99  ±  3 
* Frequencies  of B lymphocytes were as follows: 16.3 +  3.9% Ig*-B ceils,  10.2 4-  4.3% p+-B cells, 
10.1  ±  3.9% B+-B cells, 5.8 ±  2.1% y+-B cells, and 2.1  ±  0.9% ot+-B ceils. All values are expressed 
as mean ±  SD. 
more  frequently  on  lymphocytes  expressing /x-,  B-,  or  3,-heavy  chains  than  those 
expressing a-chain. The combined frequencies of/~+, B  +, and 3,+-cells among Id  + cells, 
determined independently, added to >200%. This is consistent with the co-expression 
of/1- and  &chains by  most  B  lymphocytes, and  the observation that  approximately 
one-third of 3,+-B-lymphocytes in adult blood also express/~- and/or  &chains (13).  In 
these  experiments, cells  were  allowed  to  cap  after  exposure  to  anti-Id  and  before 
staining for Ig isotype under conditions which prevented capping. We never observed 
independent  distribution of the two fluorochromes, indicating that  anti-ld and anti- 
isotype antibodies were reacting with the same molecules. 
Anti-Id  (001),  raised  to an  IgA~  myeloma, recognized sIg of x- and 7t-  light-chain 
type in a  ratio of ~3:1  in seven of eight different samples of peripheral lymphocytes. 
With  anti-Id (003),  raised to an IgAx myeloma, only a  single Id+•  + cell was found in H. KUBAGAWA ET AL.  797 
the same eight samples. These data may relate to differences in the specificity of the 
two antibody preparations for idiotypic determinants of a- and light chains, respec- 
tively. Anti-Id (001) had a relatively greater affinity for homologous heavy chain than 
for  light  chain  (Fig.  1),  whereas  the  reverse was  true  for anti-Id  (003)  (data  not 
shown). The data obtained with anti-Id  (001) is consistent with the possibility that 
the Vri determinants recognized by these antibodies may be expressed in conjunction 
with several different light chain V-regions and vice-versa. In experiments in which 
cells were stained  with  both  preparations  of anti-Id  antibodies,  no doubly stained 
cells from either normal individuals or the patients were observed. 
The anti-Id antibodies reacted with normal plasma cells of all Ig classes in the same 
or slightly higher frequencies than  those obtained for B  lymphocytes. Plasma cells 
expressing both idiotypic specificites were not observed, and anti-Id antibodies did 
not  stain  representative myeloma cells of all  major  immunoglobulin  classes  (IgM, 
IgD, IgG, and IgA) and types (~¢ and ~). In cultures of peripheral blood lymphocytes 
stimulated  with  pokeweed mitogen, the  frequencies of plasma  cells containing the 
idiotypic determinants correlated closely with the frequency of Id  ÷ B lymphocytes in 
the preculture population (data not shown). 
Isolation of Subpopulations of Anti-idiotypic Antibodies.  The above observations strongly 
suggested that these two preparations of anti-Id were not detecting two unique clones 
of B cells, but rather two distinct families of cells expressing myeloma-related idiotypic 
determinants.  We therefore attempted to refine the specificity of these reagents by 
repeated absorption of 2 mg of anti-Id antibody over a column loaded with 220 mg 
of  normal  gammaglobulin  (Cohn  Fx  II  protein)  (30).  The  relative  capacity  to 
agglutinate erythrocytes coated with the homologous myeloma protein as opposed to 
erythrocytes heavily coated with  Cohn  Fx II  protein was  not  altered by five such 
absorptions (data not shown). However, the frequency of B lymphocytes reactive with 
these absorbed antibody preparations was dramatically reduced. The further absorbed 
anti-Id (001)  stained <0.03% of B lymphocytes from normal donors, as compared to 
0.8  +  0.3% for the original anti-Id (001) preparation. Absorbed and original anti-Id 
(003)  preparations stained --<0.03% and  0.5  +  0.3% of normal sIg  + B lymphocytes, 
respectively. In  view  of these  results,  the  original  preparations  of anti-Ids  will  be 
referred to as anti-myeloma related (MR) Id and the further absorbed anti-Ids with 
finer specificity as anti-individual (Ind) Id. 
Exclusive Expression of ldiotype by B Cells in Patients with Multiple Myeloma.  As shown 
in  Table  IV,  Id  +  cells  could  not  be  detected  in  the  T-cell-enriched  fraction  of 
lymphocytes from either patient, whereas from 5 to 8% of sIg  + cells in B-cell-enriched 
fractions were also stained for idiotype. 
Relationship of ldiotype to Isotype Expression by B Lymphocytes and Plasma Cells of Myeloma 
Patients.  Preparations of circulating lymphocytes and  bone marrow cells from the 
myeloma patients were simultaneously stained for surface idiotype and isotype or for 
cytoplasmic idiotype and isotype, respectively. In these experiments both anti-MR Id 
and  anti-Ind  Id  were  used.  Results  are  shown  in  Table V.  The great  majority of 
plasma cells in bone marrow from both patients were IgA-positive. Of these, >94% 
stained brightly with the corresponding anti-Id. The frequencies of Id+IgA  + plasma 
cells detected were identical whether idiotypic determinants were detected by anti- 
MR Id or anti-Ind Id, and no plasma cells containing intracytoplasmic IgM or IgG 
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TABLE  IV 
Expression of Myeloma-related Idiotypes on Peripheral B- and T-Lymphocyte 
Populations in Myeloma Patients 
Surface marker  Patient 001  Patient 003 
B-cell fraction: 
sId-sIg  ÷  19.2"  27.5 
sId+sIg  +  1.0  2.5 
sld+sIg  <0.1  <0.1 
T-ceLl fraction: 
sId-anti-T  +  61.3  68.2 
sld+anti-T  ÷  <0.05  <0.05 
sId-ER + ~:  ND§  66.6 
sId+ER+~:  ND  <0.1 
* Values are expressed as the percentage of lymphocytes with the indicated 
phenotype among each fraction. 
:~ Cells were first stained for surface idiotype, then rosettes were formed with 
neuraminidase-treated SRBC. Evaluation was done on wet-mount prepara- 
tions. 
§ Not done. 
TABLE  g 
Expression of ldiotype Determinants in Plasma Cells and B Lymphocytes  from Myeloma Patients 
Percent of Id  + cells among: 
Donor*  Anti-ld:~  Marrow plasma cells  Peripheral B lymphocytes 
IgM  IgG  IgA  sIgM  sIgD  slgG  sIgA  sIg 
001 
003 
Exp.  1  Anti-MR Id  0  0  99  18.6  8.7  7.8  13.7  11.2 
Anti-Ind Id  0  0  99  <0.4  <0.4  0.2  3.2  2.2 
Exp. 2  Anti-MR Id  ND§  ND  ND  14.4  27.4  24.3  38.1  22.4 
Anti-lnd Id  ND  ND  ND  1.6  2.1  5.4  11.1  7.1 
Anti-MR Id  0  0  94  1.3  1.5  3.5  9.6  3.1 
Anti-lnd Id  0  0  94  0.2  0.1  0.1  1.0  1.4 
* Frequencies of B lymphocytes among peripheral blood lymphocytes for patient 001 were  1.3 and  1.6% 
Ig  + B cells, 0.4 and 0.3%/~+ B cells, 0.5 and 0.6% 6  ÷ B cells, 0.5 and 0.6% y+ B cells, and 0.4 and 0.4% 
0t  + B ceils, and for patient 003, 9.6% Ig  + B cells, 7.7% #+ B cells, 6.1% 6  + B cells, 0.8% y÷ B cells, and 0.6% 
a ÷ B cells. 
Anti-Ind Id  (001)  stains <0.03% of normal B  lymphocytes, whereas anti-Ind Id  (003)  stains --<0.03%. 
Anti-MR Id and anti-lnd Id antibodies were used at the same concentration (0.5 mg/ml). 
§ Not done. 
Different  results  were  obtained  with  regard  to  Id +  B  lymphocytes.  Among  slg  + 
circulating lymphocytes  from patient  001,  11  and  22%  (in two experiments)  also had 
idiotypic  determinants  detected  by  anti-MR  Id  (001).  Idiotypic  determinants  were 
detected  on  cells  bearing  IgM,  IgD,  IgG,  and  IgA.  When  stained  with  anti-Ind  Id 
(001), the frequency of sIg  ÷ cells costained for idiotype was reduced three- to fivefold, 
and  positive cells were  largely sIgA  ÷  lymphocytes.  In one of the two experiments,  no 
lymphocytes  bearing  IgM  or IgD  were  Id ÷,  Among  sIg  +  cells from patient  003,  3.1% 
costained  with anti-MR  Id  (003)  and  1.4%  with anti-Ind  Id  (003).  Using either anti- 
Id reagent, Id ÷ cells expressing each of the major isotypes were detected, although  the 
majority of Id + cells were sIgA  +. 
In summary,  these data  indicate that  the frequency of Id + cells among  B  lympho- H. KUBAGAWA ET AL.  799 
cytes from myeloma patients  detected by anti-Ind  Id  is  50-250  times higher than 
among normal B lymphocytes. In both patients, idiotypic determinants were present 
on lymphoeytes bearing surface Ig molecules of different heavy-chain isotypes, but 
the predominant class of Id  + B lymphocytes detected by anti-Ind Id consisted of cells 
expressing the same isotype as the myeloma plasma cells. 
The anti-Ind Id antibodies apparently stain all cells belonging to their respective 
myelomatous clones. The anti-MR Id antibodies stain the same cells, and an addi- 
tional population of B lymphocytes producing immunoglobulins having related VH 
and/or VL determinants. In patient 001, for example, the difference in frequencies of 
Id  ÷ cells detected by anti-MR  Id and anti-Ind  Id was 9-15%.  The frequency of B 
lymphocytes bearing  myeloma-related idiotypes  is  therefore >I0  times  as  high  in 
patient  001  than  in  a  group of normal  donors  (0.8%  of sIg  + cells).  Similarly,  the 
relative frequency of B lymphocytes bearing myeloma-related idiotypes in patient 003 
is several fold higher than among B lymphocytes from normal donors. 
Presence of ldiotypic Determinants in Pre-B Cells  from Myeloma Patients.  Pre-B cells can 
be distinguished from B lymphocytes by the lack of surface IgM, and from plasma- 
blasts and  plasma cells by their lymphoid morphology, relatively weak cytoplasmic 
immunofluorescence, and  lack  of sIgM  (which  is  present  on  the  majority of IgM- 
containing plasma cells). Two staining techniques were used to search for pre-B cells 
containing idiotypic determinants.  In  the first, viable nucleated bone marrow cells 
were stained with  FITC anti-# or anti-F(ab')2,  fixed, and  then stained  with  RITC 
anti-Id or RITC anti-#. From such preparations the frequencies of sIgM + B lympho- 
cytes and of sIg-cIgM + pre-B cells were determined. Id  ÷ pre-B cells were defined by 
their lymphoid morphology, lack of surface Ig determinants, and weak cytoplasmic 
fluorescence with anti-Id. This method excludes the possibility of scoring sIgM+sId + 
B lymphocytes as pre-B cells, but might falsely include a population of plasmablasts 
containing small amounts of IgA of the myeloma idiotype. Control experiments were 
done to estimate the frequency of such cells.  It was first determined that virtually all 
(>99%)  IgA-containing  cells  in  the  marrow  preparations  from  either  patient  had 
detectable surface IgA. In preparations stained with anti-F(ab')2 to detect surface Ig 
and  anti-a  to detect cytoplasmic IgA,  the frequency of sIg-  cIgA  ÷ cells was  ~1  in 
20,000 nucleated cells. This was  10-fold less than the sIg-cId  + or of sIgM-cId  + cells 
with pre-B-cell morphology. 
In the second method, fixed preparations of marrow cells were stained sequentially 
with RITC anti-# and FITC anti-Id antibodies; pre-B cells were defined as lymphoid 
cells  costaining  for  IgM  and  idiotypic  determinants.  With  this  method,  some 
sIgM+cId + cells might be incorrectly scored as pre-B ceils, but cIgA+cId  + cells would 
be excluded. In one experiment, bone marrow cells were incubated on a plastic dish 
coated with anti-Ig. The frequency of sIgM + cells in the nonadherent population was 
reduced fourfold (to 0.16%), whereas the frequency of cIgM+cId  + cells was increased 
11-fold (to 0.23%). Thus, we believe most of the cells scored in this manner are indeed 
sIg- pre-B cells. 
To further limit subjectivity, slides were independently examined by four different 
observers.  Finally, two different counting methods were used  for slides  stained  for 
cIgM and cId. The frequency of cIgM÷cId  + cells as a function of nucleated cells was 
determined first. A  second observer then scanned the entire slide to determine the 
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TABLE  VI 
Expression  of ldiotype  By Pre-B Cells in Bone Marrow * 
Donor 
Months of 
treatment~ 
Date 
Reagents and Staining Procedure 
Anti-p,, fix, anti-MR Id, or  Fix, anti-p,, and  Fix, anti-/t, and 
anti-p,  anti-MR Id  anti-Ind Id 
s/t-ep.  +  sp`-cId  ÷  cp`+cld +  c#+cId  ÷ 
pre-B cell  pre-B cell  pre-B cell  pre-B cell 
001 
Normal con- 
trol 
003 
Normal con- 
trol 
0  0.13  0.06 (46)§  0.04 (3 I)  0.05 (39) 
3  0.30  oA7 (57)  0.10 (33)  NDII 
18  0.11  ND  <0.01  (<9)  0.006 (6) 
0.87  <0.003 (<0.3)  ND  ND 
6  0.32  ND  0.04 (13)  0.024 (7.5) 
14  0:32  ND  0.02 (6)  ND 
20  0.04  0.03 (75)  0.006 (15)  0.004 (10) 
0.87  --<0.005 (-<0.6)  ND  ND 
* Results are expressed as the  percentage of cells with  the indicated  phenotype among nucleated bone 
marrow cells. 
~: Patient  001  was  treated  with  prednisone  and  chlorambucil,  and  patient  003  with  prednisone  and 
melphalan. 
§ Numbers in parentheses indicate the percentage of Id  ÷ pre-B cells among total pre-B cells. 
II Not done. 
Data from these experiments are presented in Table VI. Pre-B cells were detected 
by both staining methods.  Frequency  estimates were higher when sIgM- cId+ cells 
were determined  than when cIgM+cId  + cells were scored as pre-B cells. The results 
shown were made by a single observer and are conservative; independently determined 
frequencies were either the same or higher by not more than twofold. Also shown is 
a comparison of frequencies obtained using anti-MR Id and anti-Ind Id. Pre-B cells 
were detected by either reagent in approximately the same numbers. 
In  preparations  of normal  marrow,  no  pre-B  cells  (sIgM-cId  +)  stained  for  the 
idiotype among 450 cells examined with either the anti-MR Id  (001)  or anti-Ind Id 
(001). A single positive cell was observed with MR anti-Id (003). In other experiments 
using anti-MR Id to stain normal or fetal bone marrow, the frequency of Id  + pre-B 
cells has never exceeded  1%, and most specimens have lacked positive cells (31). Our 
results, therefore, indicate that the frequency of pre-B cells bearing the homologous 
idiotype is significantly increased in myeloma patients. The proportionate increase of 
Id  ÷ pre-B cells was greater than that  for circulating Id  + B lymphocytes determined 
simultaneously. 
Discussion 
In the course of these studies on the extent of clonal involvement in IgA myelomas 
in two individuals, we prepared two distinct sets of anti-idiotype antibodies for each 
myeloma protein. Purified antibodies to the IgA~ and IgA~ myeloma proteins obtained 
by the initial series of absorptions using affinity columns did not react with myeloma 
proteins matched with respect to light-chain type, heavy-chain class, and VH and Vc 
subgroups.  The specificity of these reagents was largely directed  towards conforma- 
tional determinants of combined heavy and light chains, because the isolated chains H. KUBAGAWA ET AL.  801 
had 100- to 5,000-fold less inhibitory capacity than the intact proteins in an inhibition 
radioimmunoassay.  Using either this assay or a  direct hemagglutination  assay,  the 
frequency of Id ÷ molecules among normal serum immunoglobulins was estimated to 
be no greater than  1 in  106, a  figure in agreement with that reported by Kunkel for 
individual  myeloma-specific antibodies  (32).  However, fluorochrome conjugates of 
these anti-Id reagents stained 0.5-0.8% of sIg  + cells from normal individuals, frequen- 
cies several orders of magnitude higher than might be expected for individual clones. 
Some investigators  using  immunofluorescence techniques  have  reported similar  or 
higher frequencies of sId ÷ lymphocytes in normal individuals  (2, 4, 33, 34), whereas 
others have detected none (5, 8, 9, 35). Therefore, the purified anti-Id antibodies were 
passed repeatedly over affinity columns containing large amounts of pooled human 
gammaglobulin. The frequency ofsId  ÷ ceils was thereby reduced to <0.03% of normal 
B lymphocytes. This procedure provided a derivative set of anti-Id antibodies having 
narrow specificity; the paired sets of reagents were called anti-MR Id and anti-Ind Id 
for reasons outlined below. 
In support of the interpretation that  the initial  anti-Id reagents were specific for 
myeloma-related idiotypic determinants are the following observations:  (a)  staining 
of normal lymphocytes by anti-MR Id could be completely inhibited by the homol- 
ogous myeloma, but was not inhibited by myelomas of the same heavy-chain isotype, 
light-chain class and VH and VL subgroups;  (b) anti-MR Id antibodies did not stain 
plasma cells from other patients with myeloma (/~-, 8-, y-, a  heavy chains, x- and ~- 
light chains);  (c)  anti-Id antibodies costained lymphocytes bearing/~-, 6-,  y-, and a- 
isotypic determinants,  and, in  the case of anti-Id  (IgA~),  lymphocytes bearing both 
I¢- and h-light chains;  (d)  the frequency of sId + lymphocytes among B lymphocytes 
from normal donors was similar to the frequency of cId  + plasma cells among total 
plasma cells in cultures stimulated with pokeweed mitogen, and  (e) idiotypic deter- 
minants were detected in cells containing IgM, IgG, and IgA immunoglobulins. The 
sum of our observations on reagent specificity is most consistent with the following 
interpretation: the anti-MR Id antibodies detect a  family of clones expressing anti- 
bodies with structurally-related Id determinants whereas the derivative anti-Ind  Id 
antibodies react with a more restricted set of idiotypes within the same family. 
Neither  set  of anti-Id  preparations  reacted  with  T  lymphocytes  from  the  two 
patients or from normals. The differences between this observation and that of several 
laboratories supporting the existence of idiotypic determinants on T  lymphocytes (5, 
6, 33, 36-38), might be based upon the properties of different anti-Id preparations or 
upon  differences in  the  patients.  We  have  also  failed  to  find  Id  +  T  cells  in  two 
additional myeloma patients with IgM and IgD paraproteins. 
Idiotypic determinants expressed by plasma cells from our IgA-myeloma patients 
were restricted to IgA-producing cells, and were detected equally by anti-MR Id and 
anti-Ind  Id.  This was  not  true  for B  lymphocytes. First,  lymphocytes bearing cell 
surface IgM, IgD, and IgG as well as IgA were costained for Id. Secondly, anti-MR 
Ids stained  substantially  higher proportions of B  cells than  did  anti-Ind  Ids.  This 
suggests the existence of two expanded populations of B lymphocytes in our patients. 
One, detected by the anti-Ind Id, includes primarily cells bearing the unique myeloma 
idiotype;  a  high  proportion  of these  cells  express  the  same  isotype  (IgA)  as  the 
myeloma. The second population, represented by the difference in frequencies of Id  ÷ 
cells detected by anti-MR Id and anti-Ind Id, consists of cells expressing related but 802  IDIOTYPE EXPRESSION IN PRECURSORS OF MYELOMA CELLS 
not  identical  idiotypes  which  are  expressed  predominantly  on  sIgM  +  and  sIgD  ÷ 
lymphocytes. This second population appeared to be 2-10 times as frequent among 
B lymphocytes from the patients than among normal B lymphocytes. 
The mechanism responsible for the apparent expansion of B-cell clones expressing 
idiotypes related to the myelomatous clone is unknown. One interesting possibility is 
suggested  by  the  network  hypothesis,  which  proposes  that  immune  responses  are 
regulated, in part, by formation of auto anti-idiotypic antibodies (39). Treatment of 
mice with heterologous anti-idiotypic antibodies ~results  in an expansion of clones of 
B cells expressing that idiotype similar to the expansion induced by specific antigen 
(40).  Whether antigen or anti-idiotypic antibodies are used for priming, only about 
one-half of the  expanded  clones of Id  +  cells  produce antibodies  reactive with  the 
appropriate  antigen  (40,  41).  The  Id  + clones reactive with  the relevant antigen  in 
these systems might  be considered analogous to the unique  myeloma clone in  our 
patients,  whereas  the  clones  with  related  idiotypes, but  different combining sites, 
could be similar to the clones detected by anti-MR Id. 
The correspondence of frequencies of plasma  cells  detected by anti-MR  Id  and 
anti-Ind  Id in our patients and  the failure to find Id  + plasma cells of classes other 
than IgA, suggests that the population of B lymphocytes detected by anti-MR Id was 
not induced to undergo terminal differentiation. 
Observations in this and earlier studies (2-7) that the myeloma idiotype is expressed 
by a  high proportion of B  lymphocytes in patients  imply that  the oncogenic event 
occurs at an earlier stage of B-cell differentiation than the plasma cell. The concept 
is  supported  by our finding  that  among  the  Id  ÷  B  lymphocytes were populations 
expressing sIgM, sIgG, and sIgD, as well as sIgA. Because all B-cell clones appear to 
go through  a  developmental phase  during which  all cells express IgM  only before 
giving rise to B  cells expressing the other immunoglobulin classes  (13,  42, 43),  the 
oncogenic event in both patients must have occurred at least as early as the immature 
sIgM ÷ B lymphocyte. 
Consistent  with  this  interpretation, we observed what  appeared  to be Id  ÷ pre-B 
cells  of the  myeloma  clones.  In  contrast  to  our  observations  on  B  lymphocytes, 
frequencies of pre-B cells determined with anti-MR Id and anti-Ind Id preparations 
were  virtually  identical.  This observation  suggests  that  the  Id  +  pre-B  cells  in  the 
patients belong to the unique myeloma clone rather than idiotypically related clones. 
It follows that the expanded population of B lymphocytes expressing myeioma-related 
idiotypes in the myeloma patients is probably not derived from an expanded popu- 
lation  of pre-B  cells.  This  idea  is  consistent  with  the  speculation  that  auto-anti- 
idiotypic  antibodies  or  T  cells  with  anti-idiotypic  receptors  may  play  a  role  in 
generating  the  increased  proportion  of MR  Id  +  B  lymphocytes.  Neither  anti-Id 
antibodies nor T  cells would be expected to influence pre-B cells of myeloma related 
clones because pre-B cells lack easily detectable sIg (44), and have been shown not to 
be numerically or functionally influenced by exposure to anti-IgM antibodies under 
conditions  in  which  development  of B  lymphocytes  and  plasma  cells  is  almost 
completely blocked (17). 
The demonstration of idiotypic determinants  in  pre-B cells has other important 
implications.  We have previously shown  that  pre-B cells from rabbits  may express 
light chains as well as/t-chains, and that pre-B cells from rabbits heterozygous for b 
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The a-locus determinants, markers for heavy-chain V-region immunoglobulin genes, 
are also expressed in rabbit pre-B cells (Gathings, W. E. et al., unpublished material). 
The present  observations indicate that  human  pre-B cells also express products of 
immunoglobulin V  genes. This evidence provides strong support for the concept that 
generation of antibody diversity begins at the pre-B-cell stage of development. 
Finally, our evidence for the presence of Id  + pre-B cells in these patients strongly 
suggests  that  the clonal oncogenic event that  ultimately results in myeloma occurs 
within the bone marrow at the very earliest stage in B-cell development, and is not 
the consequence of antigen stimulation. This is in keeping with observations in mice 
indicating that T-cell malignancies invariably begin within the thymus  (45)  and in 
chickens that a  B-cell malignancy originates within the bursal inductive microenvi- 
ronment (46). Evidence from studies of malignancies of a variety of cell types suggests 
that  the target cells for the oncogenic event are immature cells within the microen- 
vironments in which they are normally induced to undergo specialized differentiation 
(47). 
Compelling arguments  have been made by Cairns  (48)  and  Mintz  (49)  that  the 
target cells for malignancies are invariably stem cells.  Studies of mouse embryonic 
teratocarcinomas show that affected stem cells may continue to differentiate normally 
following the  oncogenic event  (50).  The  validity of these  principles  in  humans  is 
attested by observations of the myeloproliferative diseases, polycythemia vera, and 
chronic myelogenous leukemia. In the former, the hyperplastic line of erythroid cells 
derives from a  stem cell that also gives rise to myelomonocytic and megakaryocytic 
cells but not the T  and B cells (51).  Transformation of an even more primitive stem 
cell apparently occurs in  patients with chronic myelogenous leukemia, in which  B 
cells,  erythrocytes, myeloid  cells,  and  megakaryocytic cells  share  the  same  clonal 
marker (52, 53). After treatment, chronic myelogenous leukemia may be replaced by 
a  lymphoid  leukemia  involving the  same  clone  (54);  in  two  such  individuals  the 
malignant lymphoblasts were found to exhibit the pre-B-cell phenotype (55).  2 
In patients with acute lymphocytic leukemia of the pre-B-cell phenotype (21), the 
malignant pre-B cells apparently cannot differentiate to functional B lymphocytes or 
plasma cells. This study suggests a different scenario for myeloma. Pre-B cells or their 
stem-cell precursors are apparently the target for the oncogenic event, but they are 
not prevented from further differentiation and do not behave as malignant cells.  In 
light  of these  observations,  it  seems  likely that  other  B-cell  malignancies,  such  as 
chronic lymphocytic leukemia, Burkitt's lymphoma, B-cell lymphomas, and Walden- 
strgm's macroglobulinemia, could reflect oncogenic events which occur at a stem cell 
level but differ in their effects on further differentiation of affected clones. 
Summary 
IgA myeloma proteins of ~-  and  X-types were isolated  from two patients.  These 
were used to produce and purify anti-idiotype antibodies of both broad (myeloma- 
related) and narrow (individual myeloma) specificities. The anti-idiotype antibodies 
were conjugated with fluorochromes and used as immunofluorescent probes to trace 
2  Greaves,  M. F., W. Verbi, L. B. Vogler, M. D. Cooper, R. Ellis, K. Ganeshaguru, V. Hofibrand, G. 
Janossy and F. J. Bollum. Antigenic and enzymatic phenotypes  of the pre-B subclass of acute lymphoblastic 
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in the patients clonal expansion at different levels of B-cell differentiation. Our results 
(a)  confirm that  B lymphocyte precursors in IgA plasma-cell myelomas are involved 
in the malignant process, (b) show that B lymphocytes of the malignant clone include 
those expressing each of the major heavy-chain isotypes, #, & y, and a, and (c) provide 
strong circumstantial  evidence  that  pre-B-cell  members  of the  malignant  clone are 
also  increased  in  frequency.  T  cells  expressing  idiotypic  determinants  were  not 
detected. These findings argue that the initial oncogenic event may occur in a B-stem 
cell and is not influenced through stimulation  by antigen.  An interesting association 
was the increased  frequency of related  clones of B  lymphocytes as detected  by their 
reactivity with anti-idiotype antibodies  of broad specificity.  Neither  plasma cell nor 
pre-B-cell members of these related clones were increased in frequency. Anti-idiotype 
antibodies or helper T  cells reactive with myeloma-related idiotypes could be respon- 
sible  for  this  phenomenon.  We  discuss  other  implications  of these  findings  and 
speculate that all of the various phenotypes of B-lineage malignancies may result from 
oncogenic processes affecting stem cell targets. 
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